<DOC>
	<DOCNO>NCT02144077</DOCNO>
	<brief_summary>The aim study test effectiveness safety medicine Ameluz® , use photodynamic therapy ( PDT ) , treat thin , non-aggressive rodent ulcer .</brief_summary>
	<brief_title>Safety Efficacy Study Treatment Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy</brief_title>
	<detailed_description>The treatment comprise 2 PDT cycle , two PDT session one week apart . If 12 week second PDT lesion completely clear patient enter follow-up phase . In case remain lesion patient receive second PDT cycle start day .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<mesh_term>Methyl 5-aminolevulinate</mesh_term>
	<criteria>Main Willing able sign inform consent form ; obtain write start study procedure Presence 13 thin ( ≤2 mm thickness ) , clinically nonaggressive , primary BCC lesion ( primary superficial , nodular , mixed superficial/nodular ) face/forehead , bald scalp , extremity and/or neck/trunk . Confirmation nonaggressiveness thickness BCC biopsies take screen least one lesion . Lesions noneligible accord biopsy timely remove surgery cryotherapy Diameters lesion range ≥0.5cm ≤2cm ; total maximal treat area 10cm² ( include 0.51.0cm margin surround lesion ) Target BCC lesion must discrete quantifiable locate within 12 treatment area Free significant physical abnormality ( eg tattoo , dermatosis ) potential treatment area may cause difficulty examination final evaluation Accept abstain extensive sunbathing use solarium observer blind part . Patients sunburn within treatment area include fully recover Healthy patient patient clinically stable medical condition , include , limited control hypertension , diabetes mellitus type II , hypercholesterolemia , osteoarthritis , permit include study medication prohibit protocol Women childbearing potential permit participate study negative serum pregnancy test screen willingness use highly effective method contraception observer blind part Main History hypersensitivity 5ALA ingredient BF200 ALA , MAL ingredient Metvix® , include arachis oil , peanut soya Hypersensitivity porphyrins Current treatment immunosuppression therapy Presence porphyria Presence BCC lesion embryonic fusion plane ( Hzone ) Presence 3 BCCs Presence malignant benign tumor skin nonaggressive BCC within treatment area ( eg malignant melanoma , squamous cell carcinoma ( SCC ) , aggressive BCC clinically diagnose screen ) within last 12 week Gorlin Syndrome Xeroderma pigmentosum Presence photodermatoses Treatment lesion ( actinic keratosis ( AK ) , BCC , SCC , Bowens disease , melanoma ) ≤12 week prior first PDT , except physical treatment ( eg cryosurgery , excision surgery ) allow ≤6 week prior first PDT ( Visit 2 ) . Lesion ( ) seem eligible clinically could confirm biopsy , locate ≥10cm eligible lesion timely remove physically Presence inherit acquire coagulation defect Start intake medication hypericin systemicallyacting drug phototoxic photoallergic potential within 8 week prior screen Clinically relevant cardiovascular , hepatic , renal , neurologic , endocrine , major systemic disease make implementation protocol interpretation study result difficult Evidence clinically significant ( CS ) , unstable medical condition , eg : Metastatic tumor tumor high probability metastasis Cardiovascular disease ( New York Heart Association [ NYHA ] class III , IV ) Immunosuppressive condition Hematologic , hepatic , renal , neurologic , endocrine condition Collagenvascular condition Gastrointestinal condition Topical treatment 5ALA MAL outside treatment area observer blind part Any topical treatment include diclofenac immunomodulatory agent ( eg imiquimod , ingenol mebutate ) 12 week prior first PDT session observer blind part Any physical treatment observer blind part within treat target area exception lesion ( ) determine noneligible biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>PDT</keyword>
	<keyword>non-aggressive BCC</keyword>
</DOC>